Swiss specialty chemical maker Clariant has signed a memorandum of understanding to enter into a strategic partnership with Saudi Arabian firm SABIC. This will result in a major restructuring of the company along with changes in management and the board of directors.
This content was published on
2 minutes
swissinfo.ch/mga
العربية
ar
“كلاريان” تعلن ابرامها اتفاقا استراتيجيا شاملا مع شريك سعودي
On Tuesday, Clariant said the collaboration will see the merger of units from both companies into a new High Performance Materials division. This will focus on producing a range of thermoplastics products for the smart electronics, health care, aerospace, automotive, robotics, additive manufacturing, renewable energy, and e-mobility sectors.
Some other business lines, including Clariant’s medical specialties unit, will be sold off by 2020 when the deal with SABIC is expected to be completed, pending regulatory approval. Earlier this month, SABIC took a 25% stake in Clariant.
Clariant said it would have a majority business stake in the collaboration, which it estimates will result in boosting sales to CHF9 billion ($9.4 billion) by 2021 (compared to CHF6.4 billion in 2017). The company made no mention in its media release if the changes would affect jobs at the Basel headquartered firm.
Current Clariant CEO Hariolf Kottmann will become chairman of an expanded board of directors, that will in future include four SABIC nominees. SABIC executive Ernesto Occhiello will take over from Kottmann as CEO.
“The portfolio upgrade together with the continuation of Clariant’s strategy enables the group to realise a significant step change into higher value specialties, which will allow the group to considerably augment value creation for all our stakeholders,” said Kottmann in a statement.
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharmaceutical bosses remain best paid CEOs
This content was published on
Novartis’ Joe Jimenez earned CHF13.2 million ($16 million) last year, while Severin Schwan of crosstown competitor Roche raked in CHF11.9 million. The two men already had the highest salaries in 2012. Third place went to Transocean CEO Steven L. Newman who took home an estimated CHF11.6 million, although that figure has yet to be confirmed…
This content was published on
Basel-based specialty chemicals company Clariant on Wednesday posted a rise in net profit to SFr40 million ($49.80 million), but this was lower than had been forecast. Clariant warned in its statement that raw material prices would rise in the second half after a sharp increase in the second quarter. The chemicals maker Lonza Group, also…
This content was published on
Clariant, based at Muttenz near Basel, on Wednesday posted a fourth-quarter net profit of SFr47 million ($48.8 million). A Reuters poll had predicted a net loss of SFr5.4 million. The group, which makes products that end up in a variety of goods, from shampoos to tyres and flat screen televisions, said it was looking forward…
This content was published on
The Basel-based firm cut more than 3,000 of its workforce last year, and at the end of 2009 employed less than 18,000 people worldwide. A Clariant spokesman confirmed the report in the Sonntag newspaper, saying that employees at Swiss plants could also be affected by the measure. The Swiss company, along with many in the…
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.